SHL to participate in 2019 PDA Universe of Pre-filled Syringes and Injection Devices

Press Release News 201910 Pda 2019

SHL is set to join one of the Parenteral Drug Association’s (PDA) key annual conferences, the Universe of Pre-filled Syringes and Injection Devices. For the first time since its inception, the PDA event will be hosted in Gothenburg, Sweden. SHL founder and President Roger Samuelsson grew up in the Gothenburg area during his formative years, later on establishing the global company it is today. Sweden is a key strategic location in which SHL has a design center and where talented designers and engineers develop breakthrough drug delivery solutions for pharmaceutical clients.

This year’s agenda highlights an important goal of continuous research and innovation in the medical device industry – to advance drug delivery systems that help improve patient quality of life.

Now in its 30th year, SHL has significantly helped pharmaceutical companies redefine how patients self-inject drugs outside hospitals. Over the years, SHL has been inciting changes and expanding its scope of vision, and this has helped shape the SHL perspective towards the development of its line of products.

Earlier this year, a combination product for type II diabetes equipped with SHL’s Needle Isolation Technology (NIT®) received the Medical Design Excellence Awards. NIT® is SHL’s proprietary safety solution for cartridge-based autoinjectors. NIT® features a pre-installed needle that is permanently hidden throughout the injection process, thus eliminating the need for patients to manually attach the needle before each injection. SHL offers a full range of solutions for all types of subcutaneous and intramuscular formulations for self-injections including Maggie®, an injector built with NIT® able to deliver highly viscous formulations and accommodate fill volumes up to 3mL.

Magnus Fastmarken, SHL Global Marketing Director said, “For more than 20 years, the SHL perspective is what has kept us at the forefront of the autoinjector industry, delivering drug-device solutions to pharmaceutical companies and their patients. The opening of our brand new manufacturing facility in Taoyuan, Taiwan is an important milestone to meet future customer needs and set a new standard in manufacturing.”

SHL has continuously established an array of in-house manufacturing and testing capabilities. This gives SHL a unique position – having full control of all processes in order to ensure that project requirements are always met. Part of this year’s two-day agenda is a talk by SHL experts Gilbert Fluetsch and Lucy Chung titled, “Modularizing Assembly and Testing Equipment for Auto and Pen Injectors.” QuiO Technologies co-founder Alexander Dahmani will give a presentation titled, “Software and Services to Transform Drugs into Disease Management Solutions.” QuiO Technologies is SHL’s official partner in connected therapeutics.

The PDA Europe conference will be held between October 22 to 23 at the Swedish Exhibition and Congress Center in Gothenburg, Sweden.

About SHL Medical

SHL Medical is a world-leading solutions provider in the design, development, and manufacturing of advanced delivery devices such as autoinjectors, pen injectors, and advanced inhaler and wearable drug delivery systems. We offer final assembly, labeling, and packaging solutions for our drug delivery devices, and also provide contract manufacturing and engineering services for the production of complex medtech and industrial products.

With locations in Switzerland, Taiwan, Sweden, and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investments in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high-volume and high-viscosity formulations and can be enhanced through digital implementations.

For additional information, visit

Media contact:


Related News